Testing puerarin for weight loss in adults with obesity

Trial details

Who runs it

Ruijin Hospital

Trial code

NCT06968208

Record updated

21 May 2025

Original description

This randomized controlled trial aims to evaluate the therapeutic efficacy of puerarin intervention in weight management and metabolic regulation among obese populations. The study will systematically address two primary endpoints: 1) The capacity of puerarin to induce clinically significant body weight reduction in individuals with BMI ≥30 kg/m²; 2) Its modulatory effects on postprandial lipid metabolism as measured by serum lipids and quantitative fecal lipid excretion analysis. Secondary outcomes focus on puerarin's pleiotropic effects, including continuous glucose monitoring-derived glycemic parameters and indirect calorimetry-assessed resting metabolic rate. Secondary exploratory objectives include investigating puerarin's potential mechanisms of action through continuous glucose monitoring and indirect calorimetry measurements to assess glycemic variability and resting energy expenditure, respectively. Participants will be randomized into two parallel groups: the intervention group receiving daily oral puerarin injection (75 mg/day, dissolved in 100 mL of 0.9% sodium chloride solution) and the control group receiving matched blank 100 mL of 0.9% sodium chloride solution, both administered double-blind for 6 consecutive months. Primary efficacy endpoints (body weight, waist circumference, lipid profile) and safety monitoring (adverse events, hematological/ biochemical parameters) will be assessed at baseline, 1, 3, and 6 months post-intervention.Read full original descriptionShow less

Randomized Controlled Trial of Puerarin for Obesity Treatment

This randomized controlled trial aims to evaluate the therapeutic efficacy of puerarin intervention in weight management and metabolic regulation among obese populations. The study will systematically address two primary endpoints: 1) The capacity of puerarin to induce clinically significant body weight reduction in individuals with BMI ≥30 kg/m²; 2) Its modulatory effects on postprandial lipid metabolism as measured by serum lipids and quantitative fecal lipid excretion analysis. Secondary outcomes focus on puerarin's pleiotropic effects, including continuous glucose monitoring-derived glycemic parameters and indirect calorimetry-assessed resting metabolic rate. Secondary exploratory objectives include investigating puerarin's potential mechanisms of action through continuous glucose monitoring and indirect calorimetry measurements to assess glycemic variability and resting energy expenditure, respectively. Participants will be randomized into two parallel groups: the intervention group receiving daily oral puerarin injection (75 mg/day, dissolved in 100 mL of 0.9% sodium chloride solution) and the control group receiving matched blank 100 mL of 0.9% sodium chloride solution, both administered double-blind for 6 consecutive months. Primary efficacy endpoints (body weight, waist circumference, lipid profile) and safety monitoring (adverse events, hematological/ biochemical parameters) will be assessed at baseline, 1, 3, and 6 months post-intervention.

Inclusion: Aged 18-60 years (inclusive), any gender; Obesity (BMI ≥30.0 kg/m²); With or without obesity-related metabolic comorbidities (e.g., type 2 diabetes, hypertension, dyslipidemia, hyperuricemia); No prior use of weight-control, glucose-lowering, or lipid-modifying medications; Stable weight (<3% fluctuation) and lifestyle for ≥1 month prior to screening; Fully informed of trial objectives, procedures, risks, and benefits; voluntarily signed informed consent form.

Exclusion: Use of weight-control medications (e.g., metformin, GLP-1 receptor agonists, orlistat), corticosteroids (oral/IV/IM/non-oral systemic/intra-articular), or metabolic-interfering drugs/supplements within 3 months prior to screening or during the trial; Use of traditional Chinese medicines or herbal products for weight management within 3 months prior to screening or during the trial; Gastrointestinal surgery within 1 year (excluding appendectomy/hernia repair) or major non-GI surgery within 6 months; Participation in other clinical trials within 3 months prior to screening; Secondary causes of obesity (e.g., monogenic obesity, Cushing's syndrome, drug-induced obesity); History of common nutrient allergies (e.g., gluten, milk, eggs, plant-derived proteins); History of psychiatric disorders, epilepsy, antidepressant use, or ongoing antiepileptic therapy; Active infectious diseases (e.g., HBV, HCV, tuberculosis, syphilis, HIV); Known hypersensitivity to trial drug components or history of severe drug allergies; Severe cardiac disorders (e.g., congenital/rheumatic heart disease, cardiomyopathy [NYHA ≥III], coronary stenting); History of malignancies (treated/untreated), regardless of recurrence status; Gastrointestinal disorders affecting absorption (e.g., IBD, active ulcers, severe diarrhea/constipation); Any condition deemed unsuitable by investigators; Severe infections, severe anemia (Hb <8 g/dL), or neutropenia (ANC <1.5×10⁹/L); Hepatic/renal dysfunction: ALT/AST ≥2.5×ULN, serum creatinine >ULN, or eGFR <60 mL/min/1.73m² (MDRD formula); Pregnancy, lactation, or plans for pregnancy within 6 months post-trial; Active substance/alcohol abuse; Hyperthyroidism or hypothyroidism.

ClinicalTrials.gov NCT06968208